Reporting in the Oct. 14 issue of The American Journal of Medicine, Kristopher Ahn, M.D., and Rukma Govindu, M.D., describe a case of an otherwise healthy 36-year-old African American woman who presents to the emergency department for treatment of a long-lasting skin rash. As her ED visit unfolds, it turns into a complicated, challenging, difficult to diagnose case. Learn more in this featured case study.
A review in the journal Lupus examines treatments for primary and secondary thromboprophylaxis in patients with anti-phospholipid autoantibodies (aPL) and a history of thrombosis, which can affect more than 50 percent of people with systemic lupus erythematosus.
In a review that examines the use of conventional and orphan autoantibodies as biomarkers for diagnosing systemic lupus erythematosus (SLE), researchers say the science is advancing rapidly with the goal of diagnosing lupus earlier than currently done.
Sjögren’s syndrome secondary to systemic lupus erythematosus (SLE) rises in frequency with age, affects around one-quarter of all people with systemic lupus, and, despite less internal organ involvement than in systemic lupus without Sjögren’s syndrome, is marked by a systemic inflammatory state with high levels of pro-inflammatory cytokines, say researchers writing in The Journal of Rheumatology this month.
The incidence of retinopathy among systemic lupus erythematosus (SLE) patents treated with hydroxychloroquine increased with longer treatment duration, but could be predicted by monitoring blood levels of the drug, say researchers writing in Arthritis & Rheumatology this month.
Roche announced this week that the U.S. Food and Drug Administration granted breakthrough therapy designation of obinutuzumab (Gazyva) for lupus nephritis, a major morbidity of systemic lupus erythematosus (SLE).
Investigators are currently pursuing at least 50 possible new treatments, or treatment targets, for systemic lupus and lupus nephritis. We're tracking the studies and in this slideshow, we highlight the results from nine new studies on lupus nephritis.
Low-dose interleukin-2 (IL-2) was found to be safe and well tolerated in a phase 1 and 2a trial of 12 patients with systemic lupus erythematosus (SLE). The treatment may be beneficial in reducing disease activity, researchers report in Sept. 1 issue of The Lancet Rheumatology.
A new study published in the journal Arthritis & Rheumatology finds there may be a genetic explanation for the development of systemic lupus erythematosus (SLE) in African American women.
Anifrolumab, a potential new for lupus, just successfully completed a phase three clinical trial in which patients demonstrated reduced disease activity by significant margins, according to a statement issued by the drug’s maker AstraZeneca.